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https://doi.org/10.1016/j.trsl.2021.0In order to assess whether previous hepatic IR (Hepatic-IRfasting) and beta-cell func-
tionality could modulate type 2 diabetes remission and the need for starting glu-
cose-lowering treatment, newly-diagnosed type 2 diabetes participants who had
never received glucose-lowering treatment (190 out of 1002) from the CORonary
Diet Intervention with Olive oil and cardiovascular PREVention study (a prospective,
randomized and controlled clinical trial), were randomized to consume a Mediter-
ranean or a low-fat diet. Type 2 diabetes remission was defined according to the
American Diabetes Association recommendation for levels of HbA1c, fasting
plasma glucose and 2h plasma glucose after oral glucose tolerance test, and hav-
ing maintained them for at least 2 consecutive years. Patients were classified
according to the median of Hepatic-IRfasting and beta-cell functionality, measured
as the disposition index (DI) at baseline. Cox proportional hazards regression deter-
mined the potential for Hepatic-IRfasting and DI indexes as predictors of diabetes
remission and the probability of starting pharmacological treatment after a 5-year
follow-up. Low-Hepatic-IRfasting or high-DI patients had a higher probability of dia-
betes remission than high-Hepatic-IRfasting or low-DI subjects (HR:1.79; 95% CI
1.063.05; and HR:2.66; 95% CI 1.604.43, respectively) after a dietary intervention
with no pharmacological treatment and no weight loss. The combination of low-
Hepatic-IRfasting and high-DI presented the highest probability of remission (HR:4.63;
95% CI 2.0010.70). Among patients maintaining diabetes, those with high-
Hepatic-IRfasting and low-DI showed the highest risk of starting glucose-loweringto this work.
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Volume 238 Roncero-Ramos et al 13therapy (HR:3.24;95% CI 1.507.02). Newly-diagnosed type 2 diabetes patients with
better beta-cell functionality and lower Hepatic-IRfasting had a higher probability of
type 2 diabetes remission in a dietary intervention without pharmacological treat-
ment or weight loss, whereas among patients not achieving remission, those with
worse beta-cell functionality and higher Hepatic-IRfasting index had the highest risk
of starting glucose-lowering treatment after 5 years of follow-up. (Translational
Research 2021; 238:1224)
Abbreviations: Adipo-IR = Adipose tissue insulin resistance index; ALT = alanine aminotransfer-
ase; AUC = area under curve; BMI = body mass index; CHD = coronary heart disease;
CORDIOPREV = CORonary Diet Intervention with Olive oil and cardiovascular PREVention;
DBP = diastolic blood pressure; DI = disposition index; FFA = free fatty acids; HDL-c = high-den-
sity lipoprotein; Hepatic-IRfasting = hepatic insulin resistance index derived from fasting values;
IGI = insulinogenic index; ISI = insulin sensitivity index; IR = insulin resistance; LDL-c = low-density
lipoprotein; LF diet = low-fat diet; Med diet = Mediterranean diet; MISI = muscular insulin sensi-
tivity index; MUFA = monounsaturated fatty acids; OGTT = oral glucose tolerance test;
PUFA = polyunsaturated fatty acids; SBP = systolic blood pressure; T2DM = type 2 diabetes mel-
litus; TG = triglyceridesAt A Glance Commentary
Roncero-Ramos, et al.
Background
Our current knowledge regarding the etiology of
type 2 diabetes points to hepatic insulin resistance
and beta cell functionality as two 2 major abnor-
malities underlying the disease. Previous studies
have associated type 2 diabetes remission with
weight loss, together with a decrease in liver fat
content and a higher beta cell recovery.
Translational Significance
Patients with lower hepatic insulin resistance and
better beta cell functionality had a higher proba-
bility of remission without significant weight loss
or pharmacological treatment. These results sug-
gest that clinicians could identify patients with
specific phenotypes in early-diagnosed type 2 dia-
betes that could be the key to achieve higher
remission rates without weight loss or pharmaco-
logical treatment.INTRODUCTION
The prevalence of type 2 diabetes mellitus is steadily
increasing worldwide with the resulting greater socio-
economic burden on health services, the economy and
society.1,2 When diabetes is presented as a comorbidity
along with coronary heart disease (CHD), there is a
greater risk of vascular complications.3,4 The preven-
tion of type 2 diabetes should therefore be a high prior-
ity in cardiovascular patients.Two major pathophysiologic abnormalities are
known to underlie most cases of type 2 diabetes: liver
insulin resistance (IR) and defects in pancreatic beta
cell function,5-7 acting in a cyclical way, which has
been expanded into what was subsequently termed the
twin cycle hypothesis.8,9 An excess of fat accumulation
in the liver induces liver IR, causing rises in fasting
plasma glucose and triggering an increase in insulin
production. As a consequence, this phenomenon leads
to impaired pancreatic beta cell function that results in
the development of type 2 diabetes.10
It has recently been demonstrated that type 2 diabe-
tes is reversible in patients who undergo bariatric sur-
gery for obesity11-13 and follow moderate energy
restriction diets,14 counteracting the fat accumulation
in the liver and pancreas. However, the molecular
mechanisms responsible for the remission are unclear.
Some investigators have examined the involvement of
IR and beta cell functionality status at the beginning of
the disease,15,16 For instance, Wang et al demonstrated
that the status of these parameters before intense insu-
lin treatment was key for long-term remission.17 How-
ever, to the best of our knowledge, no long-term
comparisons of different dietary patterns in individuals
with hepatic IR and/or beta-cell dysfunction without
pharmacological treatment or weight loss have been
reported in cases of type 2 diabetes remission in
patients with CHD.
Thus, our objective was to evaluate whether the pre-
vious status of hepatic IR and beta cell functionality
could modulate type 2 diabetes remission rates in
newly-diagnosed type 2 diabetes in patients with CHD
from the CORDIOPREV (CORonary Diet Intervention
with Olive oil and cardiovascular PREVention) study
after dietary intervention without pharmacological
treatment. In addition, considering the group of
patients who failed to achieve remission, we aimed to
Translational Research
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bility of starting glucose-lowering treatment, according
to hepatic IR and beta cell function phenotypes.MATERIALS AND METHODS
Study subjects. The current work was conducted
within the framework of the CORDIOPREV study
(Clinicaltrials.gov NTC00924937), an ongoing pro-
spective, randomized, open, controlled trial including
1002 patients with CHD, who had their last coronary
event more than 6 months before their enrolment in 2
different dietary models for 7 years, in addition to fol-
lowing the conventional treatment for coronary heart
disease.18 The participants were randomized to receive
2 diets: a Mediterranean (Med) diet or a low-fat (LF)
diet. The inclusion and exclusion criteria have been
reported previously.18
Patients who had diabetes diagnosed at the beginning
of the study and were not receiving glucose-lowering
treatment were included in the CORDIOPREV-DIRECT
study (190 out of 1002 patients). The diabetes diagnosis
was carried out according to the American Diabetes
Association diagnosis criteria.19 Of these, 7 patients could
not be included due to their inability to perform the diag-
nostic test used in this work. Thus, the remaining 183
type 2 diabetes patients were distributed at baseline into 2
groups, according to the median of their hepatic insulin
resistance index derived from fasting values (Hepatic-
IRfasting): 89 patients who had Hepatic-IRfasting values
below the median (Low Hepatic-IRfasting group) and 93
patients who had Hepatic-IRfasting values above the
median (High Hepatic-IRfasting group). One patient could
not be classified because we were unable to obtain reli-
able Hepatic-IRfasting data for them at baseline.
The second classification of our population was carried
out according to the median of the beta cell functionality
values, measured as the disposition index (DI) at baseline.
Of the 183 patients, 89 presented disposition index values
above the median (High DI group), 90 showed disposition
index values below the median (Low DI group) and 4
patients could not be classified due to technical difficul-
ties in acquiring the baseline DI data.
The biochemical and laboratory measurements were
performed as previously described.20,21 All the patients
gave written, informed consent to participate in the
study. The trial protocol and amendments were
approved by the local ethics committee of Reina Sofia
University Hospital in Cordoba, following the Helsinki
declaration and good clinical practices.
Randomization and masking. The procedure of ran-
domization has been reported elsewhere.18 Briefly, the
randomization was based on the following variables:sex (male, female), age (under and over 60 years old)
and previous myocardial infarction (yes, no). With this
distribution, 8 different groups were created, with all
the possible combinations of the above factors, to
which the diets were assigned (block randomization).
The dietitians were the only members of the interven-
tion team to be aware of the dietary group of each par-
ticipant.
Criteria for diabetes remission. Type 2 diabetes remis-
sion was defined as HbA1c <6.5%, fasting plasma glu-
cose <126 mg/dL and 2 hours plasma glucose after 75
gr oral glucose tolerance test (OGTT) <200 mg/dL,
and maintaining these levels for at least 2 consecutive
years without the use of diabetes medication to lower
blood glucose levels. The patients were tested yearly
from the first year of follow-up and classified as remis-
sion or maintaining diabetes at fifth year of the study.
In our population, 73 patients reverted from type 2 dia-
betes after 5 years of dietary intervention, while 110
participants had not achieved remission by the end of
the follow-up period.
Glucose-lowering treatment. We also evaluated the
patients who started glucose-lowering treatment during
the follow-up period. Pharmacological treatment was
prescribed by the primary care physicians or any other
specialist who was not linked to the CORDIOPREV
study, according to the standardized recommendations
given by the international guidelines.22 None of the
CORDIOPREV study researchers were involved in the
decision to start glucose-lowering treatment in those
patients.
Study design and dietary assessment. The participants
were randomized to receive 2 diets: a Med diet or a LF
diet. The LF diet consisted of <30% total fat (<10%
saturated fat, 12%14% monounsaturated fat
(MUFA), and 6%8% polyunsaturated fat (PUFA),
15% protein, and a minimum of 55% carbohydrates.
The Med diet comprised a minimum of 35% of calories
as fat (22% MUFA fat, 6% PUFA fat, and <10% satu-
rated fat), 15% proteins, and a maximum of 50% carbo-
hydrates.18 In both diets, the cholesterol content was
adjusted to <300 mg/d.
The dietary assessment has been described
recently.23 Participants in both intervention groups
received the same intensive dietary counseling. Nutri-
tionists carried out individual interviews at baseline
and every 6 months, and quarterly group education ses-
sions were held with up to 20 participants per session
and separate sessions for each group.
Estimation of insulin resistance and beta cell function
indexes. The patients underwent a standard OGTT ana-
lyzed by the Matsuda and DeFronzo method24 every
year during the follow-up period. After an overnight
fast, blood was sampled from a vein before oral
Translational Research
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glucose load (Trutol 75; Custom Laboratories, Balti-
more, MD, USA). Blood samples were taken at 30, 60,
90 and 120 min to determine glucose and insulin con-
centrations.24 Since C-peptide was not measured, the
insulin data might be confounded by clearance. The
following indexes were calculated at baseline and
every year during the follow-up period. The hepatic
insulin resistance index derived from fasting values
(Hepatic-IRfasting) was calculated as fasting insulin
(pmol/l) £ fasting glucose (mmol/l), since, as sug-
gested by Abdul-Ghani et al,25 hepatic glucose produc-
tion (HGP) is the primary determinant of the FPG
concentration,26 and FPI concentration is the primary
regulator of HGP,27 the product of FPG and FPI pri-
marily reflects hepatic insulin resistance.25 The muscle
insulin sensitivity index (MISI) was measured accord-
ing to the Abdul-Ghani et al method21: MISI = (dG/dt)/
mean plasma insulin concentration, where dG/dt is the
rate of decay of plasma glucose concentration from its
peak value to its nadir during the OGTT. Other IR indi-
ces determined were: insulin sensitivity index
(ISI) = 10,000/x ([fasting insulin (pmol/l) £ fasting
glucose (mmol/l)] £ [mean OGTT insulin (pmol/
l)] £ [mean OGTT glucose (mmol/l)])24; and HOMA-
IR.28 Insulin secretion was measured by the insulino-
genic index (IGI): IGI = (30 min insulinfasting insu-
lin [pmol/l])/(30 min glucosefasting glucose [mmol/
l]).29 Finally, beta cell function was estimated by calcu-
lating the disposition index (DI) as follows:
DI = ISI £ [AUC30 min insulin/AUC30 min glucose],
where AUC30 min is the area under the curve between
baseline and 30 min of the OGTT for insulin (pmol/l)
and glucose (mmol/l) measurements, respectively, cal-
culated by the trapezoidal method.30 The adipose tissue
insulin resistance index (Adipo-IR) was calculated as
the product of fasting free fatty acids (FFA) x fasting
plasma insulin.31
Statistical analyses. SPSS statistical software (IBM
SPSS Statistics version 21.0) was used for statistical
analysis of the data. The normal distribution of varia-
bles was assessed using the Kolmogorov-Smirnov test.
The data are represented as the mean § SEM for con-
tinuous variables and as frequencies for categorical
variables. P values  0.05 were considered statistically
significant. The statistical differences in the metabolic
variables between groups were evaluated by 1-way
ANOVA. Qualitative variables were compared using
the Chi-square test. We used the total AUC of the dif-
ferent postprandial parameters following the trapezoid
rule to assess the magnitude of change during the post-
prandial state, as in a previous study carried out by our
group.32 A repeated-measures ANOVA test was used
to determine the statistical differences betweenvariables at baseline and during the follow-up period.
The post hoc statistical analysis was completed using
Bonferroni's multiple comparison tests. For the statisti-
cal analysis we used age, sex, BMI, fasting glucose,
use of statins, family history of diabetes, ethnicity,
HDL-cholesterol, and triglycerides as covariables.
Previous further analysis, we classified our patients
as above/below the median in each of the diabetes
indexes calculated (ISI, DI, Hepatic-IRfasting, IGI,
MISI, Adipo-IR and HOMA-IR) and performed a
logistic regression analysis in order to identify the
potential influencers in diabetes remission. The model
outcomes showed that only DI and Hepatic-IRfasting
were associated with the probability of diabetes remis-
sion (Supplemental Table 1). We sought for the rele-
vance of including BMI or weight change as a
confounding variable in the Cox models and we found
no statistical significance for weight change in our out-
comes but did for BMI, so we decided to include it in
our analysis. According to that, a Cox proportional haz-
ards model was applied to identify the potential associ-
ation of Hepatic-IRfasting, DI and its combination with
the time of type 2 diabetes remission and with the prob-
ability of initiating glucose-lowering treatment. In
order to adjust these associations, the full model was
implemented, with the following variables: sex, age,
BMI, triglycerides, HDL-c, treatment (according to
dose) with statins, family history of diabetes, and diet
consumed during the intervention. Since fasting glu-
cose was included in calculation formula for DI and
Hepatic-IRfasting, it was excluded from the Cox model
in order to avoid overestimations.RESULTS
Baseline characteristic of the participants according to
hepatic insulin resistance and beta-cell functionality
phenotypes. The characteristics of the subjects accord-
ing to the hepatic insulin resistance phenotype (High
versus Low) at baseline are shown in Table I. We
observed that the High Hepatic-IRfasting group had
higher values of BMI, waist circumference, diastolic
blood pressure (DBP), glucose, glucose 2h-OGTT,
insulin, HOMA-IR, triglycerides, alanine aminotrans-
ferase (ALT), Hepatic-IRfasting and Adipo-IR than the
Low Hepatic-IRfasting group at baseline (all, P < 0.05).
Moreover, subjects with High Hepatic-IRfasting had a
lower age (P= 0.001) and ISI (P< 0.001) compared
with the Low Hepatic-IRfasting group.
The characteristics of the subjects according to the
beta cell functionality phenotype at baseline are shown
in Table II. We found that the High DI group had lower
values of glucose, glucose 2h-OGTT, HOMA-IR and
Table I. Baseline characteristics of participants according to hepatic insulin resistance phenotype
Low hepatic-IRfasting High hepatic-IRfasting P-value
n 89 93
Men/Women (n) 74/15 78/15 0.895
Age (years) 62.2 § 1.0 57.7 § 0.9 0.001
BMI (Kg/m2) 29.6 § 0.4 32.6 § 0.5 <0.001
Waist circumference (cm) 101 § 0.9 110 § 1.1 <0.001
SBP (mm Hg) 136 § 2.1 138 § 2.1 0.374
DBP (mm Hg) 74.8 § 1.2 78.9 § 1.2 0.017
HbA1c (%, mmol/mol) 6.58 § 0.07, 48 § 0.5 6.79 § 0.09, 51 § 0.6 0.072
Glucose (mg/dl) 104 § 1.7 117 § 3.0 <0.001
Glucose 2h-OGTT (mg/dl) 191 § 7.5 218 § 9.1 0.022
Insulin (mU/l) 7.10 § 0.41 16.3 § 1.3 <0.001
HOMA-IR 2.25 § 0.08 6.28 § 0.41 <0.001
HDL-cholesterol (mg/dl) 42.7 § 1.0 40.5 § 1.1 0.122
LDL-cholesterol (mg/dl) 92.2 § 2.8 91.0 § 2.7 0.760
Triglycerides (mg/dl) 131 § 7.7 154 § 7.2 0.031
C-reactive protein (mg/L) 2.97 § 0.25 2.94 § 0.22 0.934
Use of statins (%) 87.6% 87.1% 0.912
ALT (U/L) 25.8 § 1.3 30.6 § 1.4 0.012
ISI 3.69 § 0.15 1.74 § 0.08 <0.001
DI 0.57 § 0.05 0.49 § 0.03 0.140
Hepatic-IRfasting 933 § 30 2544 § 166 <0.001
MISI 0.024 § 0.032 0.018 § 0.002 0.092
IGI 0.50 § 0.05 0.87 § 0.21 0.097
Adipo-IR 22.4 § 1.5 50.2 § 3.6 <0.001
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; ISI, insulin sensitivity index; DI, disposition index; Hepatic-IRfasting
,
hepatic insulin resistance index derived from fasting values; MISI, Muscular insulin sensitivity index; IGI, insulinogenic index; ALT, alanine amino-
transferase; OGTT, Oral Glucose Tolerance Test.
Values expressed as mean § SEM. frequencies in men/women;
One-Way ANOVA P-values. P < 0.05 indicates significant differences between groups.
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In addition, subjects with a High DI phenotype had
higher LDL-c, ISI, DI and IGI values compared with
the Low DI group.
In addition, we analyzed the change in weight and
BMI between baseline and after 5 years of intervention
according to the Hepatic-IRfasting and DI groups (Sup-
plemental Table 2). We did not observe any significant
differences in weight and BMI change values between
the groups after the intervention.
Probability of type 2 diabetes remission.We performed
a Cox proportional hazards regression analysis to deter-
mine the probability of type 2 diabetes remission
according to the hepatic insulin resistance phenotype
after 5 years of intervention (Fig 1A). Compared to the
High Hepatic-IRfasting patients (reference group), the
Low Hepatic-IRfasting patients presented a 2.3-fold
higher probability of type 2 diabetes remission (HR:
2.30; 95% CI: 1.413.73). After adjustment for all
possible confounder variables mentioned in the statisti-
cal section in the methodology, the Cox model out-
comes showed that that Low Hepatic-IRfasting patients
presented a 1.8-fold higher probability of remission
(HR: 1.79; 95% CI: 1.063.05). In addition, the model
showed the association of baseline BMI, where eachSD of lower BMI corresponded to a 1.07-fold higher
probability of remission (HR: 1.07; 95% CI:
1.011.14).
Further, we performed a second Cox analysis to
evaluate the probability of type 2 diabetes remission
according to the beta cell functionality phenotype after
5 years of intervention (Fig 1B). The results showed
that patients with higher DI values had 2.4 more proba-
bility of type 2 diabetes remission than patients with
low DI values (reference group) (HR: 2.40; 95% CI:
1.463.95). After adjustment with the variables men-
tioned above, the Cox model outcomes showed that
High DI patients presented a 2.7-fold higher probabil-
ity of remission (HR: 2.66; 95% CI: 1.60-4.43). In
addition, the model showed the association of baseline
BMI, where each SD of lower BMI represented a 1.11-
fold higher probability of remission (HR: 1.11; 95%
CI: 1.051.18).
At this point, we wondered whether the patients’ phe-
notype had the same effect in each diet on their probabil-
ity of diabetes remission. Here, we found the same effect
regardless of the diet, so these diets did not modulate
diabetes remission differently in our study groups
(Hepatic-IRfasting and DI groups) (Supplemental Table
3). In this regard, we also observed that there were no
Table II. Baseline characteristics of participants according to beta-cell functionality phenotype
Low DI High DI P-value
N 90 89
Men/Women (n) 78/12 72/17 0.295
Age (years) 59.3 § 1.0 60.3 § 1.0 0.469
BMI (Kg/m2) 30.7 § 0.4 31.6 § 0.5 0.186
Waist circumference (cm) 105 § 1.1 105 § 1.2 0.909
SBP (mm Hg) 139 § 2.3 135 § 1.9 0.184
DBP (mm Hg) 78.2 § 1.3 75.7 § 1.1 0.148
HbA1c (%, mmol/mol) 6.79 § 0.10, 51 § 0.7 6.59 § 0.07, 48 § 0.5 0.105
Glucose (mg/dl) 122 § 2.9 100 § 1.4 <0.001
Glucose 2h-OGTT (mg/dl) 244 § 8.1 165 § 6.7 <0.001
Insulin (mU/l) 12.9 § 1.3 10.8 § 0.8 0.176
HOMA-IR 5.12 § 0.47 3.57 § 0.20 0.003
HDL-cholesterol (mg/dl) 41.4 § 1.2 41.7 § 0.9 0.828
LDL-cholesterol (mg/dl) 86.2 § 2.9 96.6 § 2.6 0.008
Triglycerides (mg/dl) 143 § 7.4 144 § 7.9 0.919
C-reactive protein (mg/L) 3.02 § 0.24 2.83 § 0.23 0.558
Use of statins (%) 90% 87.6% 0.616
ALT (U/L) 28.6 § 1.3 27.8 § 1.4 0.654
ISI 2.35 § 0.14 2.99 § 0.17 0.004
DI 0.30 § 0.01 0.76 § 0.05 <0.001
Hepatic-IRfasting 2096 § 189 1446 § 81 0.002
MISI 0.023 § 0.003 0.019 § 0.002 0.393
IGI 0.36 § 0.03 1.0 § 0.2 0.004
Adipo-IR 39.4 § 3.3 33.6 § 3.0 0.200
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; ISI, insulin sensitivity index; DI, disposition index; Hepatic-IRfasting
,
hepatic insulin resistance index derived from fasting values; MISI, Muscular insulin sensitivity index; IGI, insulinogenic index; ALT, alanine amino-
transferase; OGTT, Oral Glucose Tolerance Test.
Values expressed as mean § SEM. frequencies in men/women;
One-Way ANOVA P-values. P < 0.05 indicates significant differences between groups.
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sion among the type of diet studied (x2, P= 0.741).
Finally, to evaluate which index, DI or Hepatic-
IRfasting, had a better predictive effect on the probabil-
ity of type 2 diabetes remission, we divided our
patients into 4 groups, according to the DI and
Hepatic-IRfasting values at baseline. Next, we per-
formed a Cox regression analysis to determine the
probability of type 2 diabetes remission according to
these groups (Fig 1C). The results showed that patients
with the highest values of DI and the lowest values of
Hepatic-IRfasting presented a greater probability of type
2 diabetes remission than the High Hepatic-IRfasting &
Low DI group (HR: 5.40; 95% CI 2.4711.81). The
Low Hepatic-IRfasting & Low DI and High Hepatic-
IRfasting & High DI groups presented intermediate val-
ues for probability of type 2 diabetes remission (HR:
2.80; 95% CI 1.196.60 and HR: 2.93; 95% CI
1.276.79, respectively). However, after adjustment
with the possible confounder variables, the Cox model
outcomes showed that the group of patients with the
highest values of DI and the lowest values of Hepatic-
IRfasting presented a greater probability of type 2 diabe-
tes remission than the High Hepatic-IRfasting & Low DIgroup (HR: 4.63; 95% CI 2.0010.70). Furthermore,
after adjustment, only the High Hepatic-IRfasting &
High DI groups presented a higher probability of type
2 diabetes remission in comparison with the reference
group (HR: 3.63; 95% CI 1.508.80). In addition, the
model showed the association of baseline BMI, where
each SD of lower BMI corresponded to a 1.09-fold
higher probability of remission (HR: 1.09; 95% CI:
1.021.16).
Probability of starting glucose-lowering treatment. We
performed a COX proportional hazards regression
analysis to determine the probability of starting type 2
diabetes glucose-lowering treatment according to the
hepatic insulin resistance and beta cell functionality
phenotypes during 5 years of follow-up (Fig 2). The
results showed that patients with higher Hepatic-IRfast-
ing values had a higher probability of starting type 2
diabetes pharmacological treatment (HR: 2.21; 95%
CI: 1.343.65) than the low Hepatic-IRfasting group.
Likewise, patients with lower DI values also had a
greater probability of starting glucose-lowering treat-
ment than those presenting higher DI values (HR: 1.98;
95% CI: 1.203.24). However, after adjustment with
the possible confounder variables mentioned in the
Fig 1. Probability of type 2 diabetes remission. Probability of type 2 diabetes remission according to hepatic
insulin resistance index derived from fasting values (Hepatic-IRfasting) (A), beta cell functionality measured as
disposition index (DI) (B) and the combination of Hepatic-IRfasting and DI groups (C). The graphics represent
the curves of probability without adjustment. These models were adjusted for age, sex, BMI, triglycerides,
HDL-c, treatment with statins, family history of diabetes and diet consumed during the intervention. The HR
between groups was calculated.
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Fig 2. Probability of starting glucose-lowering treatment. Probability of starting treatment for type 2 diabetes
according to hepatic insulin resistance index derived from fasting values (Hepatic-IRfasting) (A), beta-cell func-
tionality measured as disposition index (DI) (B) and the combination of Hepatic-IRfasting and DI groups (C). The
graphics represent the curves of probability without adjustment. These models were adjusted for age, sex, BMI,
triglycerides, HDL-c, treatment with statins, family history of diabetes and diet consumed during the interven-
tion. The HR between groups was calculated.
Translational Research
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higher Hepatic-IRfasting values did not increase the
probability of starting pharmacological treatment but
did show a significant association for of baseline BMI
values (HR: 1.07; 95% CI: 1.011.13) and family his-
tory of diabetes (HR: 1.66; 95% CI: 1.012.73) (Sup-
plemental Table 5). Regarding DI groups, the COX
model outcomes showed that after adjustment, those
patients with lower DI values presented a 2.23-fold
higher probability of starting treatment (HR: 2.23; 95%
CI: 1.323.76). In addition, it also showed the associa-
tion for baseline BMI values (HR: 1.11; 95% CI:
1.051.17) and family history of diabetes (HR: 1.66;
95% CI: 1.012.74) (Supplemental table 5).
At this point, we evaluated the likelihood of starting
type 2 diabetes pharmacological treatment according
to the diets consumed and hepatic insulin resistance
and beta cell functionality phenotypes to find out
whether the patients’ phenotype had the same effect in
each diet on their probability of starting treatment. We
found that the same effect was produced regardless of
the diet, so these diets did not modulate the likelihood
of starting pharmacological treatment differently in our
study groups (Supplemental Table 4).
When we evaluated the probability of starting phar-
macological treatment in the population classified
according to Hepatic-IRfasting and DI, we observed that
patients with the highest values of Hepatic-IRfasting and
the lowest values of DI presented a higher probability
of starting glucose-lowering treatment than the Low
Hepatic-IRfasting & High DI group (HR: 4.07; 95% CI:
1.938.61). The Low Hepatic-IRfasting & Low DI and
High Hepatic-IRfasting & High DI groups did not pres-
ent any differences in the probability of starting treat-
ment compared to the Low Hepatic-IRfasting & High DI
group used as a reference. The same was observed in
the COX model after adjustment with the variables
mentioned above, with the group of patients with High
Hepatic-IRfasting & Low DI presenting a 3.24-fold
higher probability of starting glucose-lowering treat-
ment than the reference group (HR: 3.24; 95% CI:
1.507.02). In this case, the model also included the
baseline BMI values (HR: 1.09; 95% CI: 1.021.16)
which are associated with starting treatment (Supple-
mental table 5).
Beta cell function and insulin resistance. We evaluated
the IR and beta cell function as assessed by the vali-
dated indexes during the follow-up period (Supplemen-
tal Fig. 1) and observed higher ISI and lower Hepatic-
IRfasting in the Low Hepatic-IRfasting group than in the
High Hepatic-IRfasting group throughout the study (P<
0.001). However, we found no significant differences
in the DI index between both groups.When we compared the DI classification groups, the
High DI group had higher DI values compared with
patients with Low DI values. Regarding the Hepatic-
IRfasting and ISI indexes, no significant differences
were observed between the DI groups.
Levels of FFA, ALT and Adipo-IR index. We evaluated
the FFA on the OGTT, carried out at baseline and after
5 years of follow-up (Supplemental Fig. 2). We
observed higher FFA plasma levels in Low DI subjects
(P= 0.044) than in the High DI group. However, we
detected no differences in FFA plasma levels between
Hepatic-IRfasting groups.
Moreover, we evaluated the Adipo-IR and ALT lev-
els at baseline and after 5 years of follow-up (Supple-
mental Fig. 2). We observed higher Adipo-IR and ALT
levels in High Hepatic-IRfasting subjects (P< 0.001 and
P= 0.017, respectively) than in the Low Hepatic-IRfast-
ing group. After that, we evaluated these parameters in
the DI groups, but found no differences in ALT levels
or Adipo-IR index between the groups.DISCUSSION
In this study, we found that patients with lower
hepatic insulin resistance values at the beginning of the
study had a higher probability of type 2 diabetes remis-
sion compared with those who had higher Hepatic-
IRfasting values after a dietary intervention without
weight loss or glucose-lowering treatment. Likewise,
patients with better beta cell functionality presented
higher type 2 diabetes remission rates than those who
had lower DI values. Therefore, we found that those
with a combination of lower Hepatic-IRfasting and
higher DI values presented the highest probability of
type 2 diabetes remission. Moreover, the group of
patients with a combination of higher Hepatic-IRfasting
and lower DI showed a higher probability of starting
pharmacological treatment for type 2 diabetes after
5 years of intervention among those patients maintain-
ing diabetes. Our results showed that previous status of
both indexes are potential contributors to type 2 diabe-
tes remission after a dietary intervention without
weight loss or pharmacological treatment. However,
only DI and its combination with Hepatic-IRfasting
influenced the probability of starting glucose-lowering
treatment in those patients who did not achieve diabe-
tes remission.
Type 2 diabetes is a multifactorial disease whose
development is dependent on environmental and
genetic factors. Its pathophysiology is mainly charac-
terized by an increase in insulin resistance and a loss of
beta cell function.33 Several authors have investigated
Translational Research
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this disease.34,35 It is crucial to gain a better under-
standing of this problem, given the fact that type 2 dia-
betes is a global health problem whose prevalence is
increasing dramatically36. In the last few decades, the
efforts of the scientific community have also been
directed towards the study of diabetes remission,
which, despite the traditional doctrine, has been shown
in recent years to be possible.37-39 Most of the authors
have associated type 2 diabetes remission with weight
loss, together with a decrease in liver fat content and
higher beta cell recovery.9,39 However, to the best of
our knowledge, these studies were based on the charac-
teristics of the participants at the beginning of studies
and remission was achieved after bariatric surgery,
pharmacological treatment or dietary intervention with
the aim of weight loss. Thus, in our study, we aimed to
go further and identify whether different pathophysio-
logical phenotypes (hepatic insulin resistance and beta
cell functionality) might provide the basis for the
development of an individualized tool to better predict
type 2 diabetes remission in response to a healthy die-
tary treatment during 5 years of follow-up in which
remission was achieved without any pharmacological
treatment or weight loss.
Our study demonstrates that diabetic patients with
lower Hepatic-IRfasting levels at baseline had a higher
probability of type 2 diabetes remission than those who
had higher values of Hepatic-IRfasting. Even though a
lower hepatic IR has already been established as a
potential factor for promoting the remission of type 2
diabetes,37,40 this effect has been associated to major
weight loss with a possible diminishing in liver fat, or
after pharmacological treatment. In our study, patients
with higher Hepatic-IRfasting values at baseline did not
experience type 2 diabetes remission, probably due to
the lower insulin sensitivity and higher hepatic IR that
they presented from the beginning of the study.
According to the twin-cycle hypothesis,9,12 fat accumu-
lation in the liver could have triggered insulin resis-
tance and initiated the cycle affecting the insulin
production by the pancreas. Moreover, the higher
hepatic IR levels found in the High Hepatic-IRfasting
group, together with their higher level of ALT after 5
years of intervention, would suggest an increase in
liver fat in those patients.41 It has been demonstrated
that increased liver fat levels are associated with
hepatic IR, inadequate suppression of hepatic glucose
production, and hence increased fasting plasma
glucose.14,42,43 Therefore, patients with High Hepatic-
IRfasting seem to have a non-reversible metabolic dys-
function, since the dietary intervention did not succeed
in improving either the IR or the adipose tissue meta-
bolic dysfunction in those patients.Beta cell damage in the early stages of type 2 diabe-
tes can be restored to normal function through diet-
induced weight loss, as has been previously demon-
strated by the DiRECT trial.37 In line with these
results, the patients with better beta cell functionality
at the beginning of our trial presented a higher proba-
bility of type 2 diabetes remission than those who had
lower DI values. These subjects, in the Low DI group,
presented lower LDL-c values at baseline, which have
been associated with higher type 2 diabetes risk44;
they also showed lower beta cell functionality values
during the 5 years of follow-up than those with higher
DI values, who probably still had a reversible meta-
bolic status. According to the twin-cycle hypothesis
proposed recently to explain the pathophysiology of
diabetes, in addition to the higher DI values which
increase the probability of remission, our results
showed that even with small increases of probability
(HR:1.1), compared to the HR of those with a higher
DI (HR:2.7), those with lower BMI values also had a
higher probability of remission, since these patients
are expected to present less fat deposit in visceral
organs such as the liver. Therefore, early intervention
with healthy diets in subjects with better beta cell
functionality at the beginning of the trial leads to a
higher probability of achieving type 2 diabetes remis-
sion, without the use of pharmacological treatment or
drastic weight loss. Our results are in agreement with
a previous study showing that patients with a better
pancreatic beta cell function before bariatric surgery
had an increased chance of type 2 diabetes remission
after the surgery.16
Further, to identify which phenotype had a better
predictive value, we divided our population, taking
into account both the hepatic insulin resistance and
beta cell functionality indexes. We found that both
indexes contribute equally to the remission of type 2
diabetes. In fact, it is the synergy of both phenotypes,
lower Hepatic-IRfasting and higher DI values, which
better predicts type 2 diabetes remission. These
results suggest that hepatic IR and beta cell function-
ality are the physiological mechanisms which contrib-
ute most to the onset of type 2 diabetes. For this
reason, identifying these phenotypes in early diag-
nosed diabetic patients could be the key to achieving
higher type 2 diabetes remission rates. In our study,
both dietary treatments (low-fat and Mediterranean
diets) exerted similar effects on type 2 diabetes remis-
sion. The 2 diets studied have similarities in terms of
the lack of caloric restriction and being considered
healthy cardioprotective dietary patterns which are
low in saturated fatty acids and high in fiber and high-
complex carbohydrates. Similarly, it has been
reported that dietary intervention in diabetic patients,
Translational Research
22 Roncero-Ramos et al December 2021such as the consumption of a hypocaloric diet for 6
months, can lead to a recovery of beta cell function, a
decrease in liver fat and a return of serum ALT to nor-
mal levels.37,45
On the other hand, there is little scientific literature
available about the risk of starting glucose-lowering
treatment in diabetic patients according to the level of
the hepatic insulin resistance and beta cell functionality
indexes. The only relevant study was published by
Esposito et al,46 reporting that a Mediterranean diet
can delay the need for antihyperglycemic drug therapy
in overweight patients with newly diagnosed type 2
diabetes. In our study, the dietary intervention led to a
lower probability of starting glucose-lowering treat-
ment only in High DI patients, due to their better glu-
cose homeostasis control and in those with a
combination of Low Hepatic-IRfasting and High DI val-
ues. In addition, our results suggest the involvement of
genetic factors associated to the increased probability
of starting pharmacological treatment, since those with
a family history of diabetes presented more probability
of initiating treatment.
The major strength of this study is that, to the best
of our knowledge, this is the first approach to assess
type 2 diabetes remission according to hepatic insulin
resistance and beta cell functionality phenotypes after
a dietary intervention with 2 healthy diets with no
caloric restriction or weight loss and without any
pharmacological treatment in patients with CVD,
which is a relevant finding, since the progression of
type 2 diabetes in these patients severely increases the
risk of a new cardiovascular event.47 However, certain
limitations should be highlighted. First, this research
is based on a long-term, well-controlled dietary inter-
vention, which ensures the quality of the study, but
may not reflect the level of compliance in a free-living
population. The second limitation is that the preven-
tion of type 2 diabetes was not the primary endpoint
of the CORDIOPREV trial, although it was a second-
ary objective of this study. And finally, since C-pep-
tide was not measured, insulin data might be
confounded by clearance. However, there are no rea-
sons to believe that the randomization would not have
worked in such a large subset of participants, taking
into account that the baseline characteristics in the
current study were similar in the groups of patients
analyzed in this study.
In conclusion, our study shows that newly-diagnosed
type 2 diabetes and coronary heart disease patients with
better beta cell functionality and lower hepatic insulin
resistance values had a higher probability of type 2 dia-
betes remission. Moreover, among patients who
remained diabetic, those with the worst beta cell func-
tionality and higher hepatic insulin resistance had ahigher risk of starting glucose-lowering treatment after
5 years of dietary intervention.ACKNOWLEDGMENTS
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